Effects of interleukin-2 on hepatitis B vaccination in uraemic patients

Cryptic T cell epitopes in polymorphic immunoglobulin regions: evidence for positive repertoire selection during fetal development.

European journal of immunology·1992

Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.

Journal of immunology (Baltimore, Md. : 1950)·1992

Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity.

European journal of immunology·1992

[Baclofen intoxication in chronic hemodialysis and kidney transplantation].

Deutsche medizinische Wochenschrift (1946)·1992

Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.

Immunology·1992

Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

Proceedings of the National Academy of Sciences of the United States of America·1992

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Lancet (London, England)·2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Lancet (London, England)·2026

Fab-Level LC-MS Assessment of Chain Pairing in Asymmetric Bispecific Antibodies Enabled by IdeS Digestion and Selective Hinge Reduction.

Pharmaceutical research·2026

Comparative and qualitative analysis of endoscopic unilateral laminectomy with bilateral decompression versus interbody fusion in the treatment of grade 1 degenerative lumbar spondylolisthesis.

Neurosurgical focus·2026

Artificial intelligence for rapid on-site evaluation of lymph node fine-needle aspiration: improving diagnostic efficiency and accuracy.

Frontiers in medicine·2026

High transmission risk of Human Immunodeficiency Virus in blood transfusions: A critical evaluation of blood bank serological tests in Mozambique.

PLOS global public health·2026

Evaluation of Prophylactic Negative Pressure Therapy in the Murine Hindlimb Lymphedema Model.

Journal of vascular research·2026

Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies.

Journal of clinical microbiology·2026

Related Experiment Videos

Effects of interleukin-2 on hepatitis B vaccination in uraemic patients

Related Concept Videos

Cryptic T cell epitopes in polymorphic immunoglobulin regions: evidence for positive repertoire selection during fetal development.

Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.

Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity.

[Baclofen intoxication in chronic hemodialysis and kidney transplantation].

Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.

Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Fab-Level LC-MS Assessment of Chain Pairing in Asymmetric Bispecific Antibodies Enabled by IdeS Digestion and Selective Hinge Reduction.

Comparative and qualitative analysis of endoscopic unilateral laminectomy with bilateral decompression versus interbody fusion in the treatment of grade 1 degenerative lumbar spondylolisthesis.

Artificial intelligence for rapid on-site evaluation of lymph node fine-needle aspiration: improving diagnostic efficiency and accuracy.

High transmission risk of Human Immunodeficiency Virus in blood transfusions: A critical evaluation of blood bank serological tests in Mozambique.

Evaluation of Prophylactic Negative Pressure Therapy in the Murine Hindlimb Lymphedema Model.

Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies.

Related Experiment Videos

Effects of interleukin-2 on hepatitis B vaccination in uraemic patients

Related Concept Videos

Related Articles